Lant Medical receives bacteria work boost

A life sciences firm has secured backing to push forward “groundbreaking” work on a leading cause of peptic ulcers.

Lant Medical is designing a clinical trial for a non-antibiotic treatment targeting Helicobacter pylori (H. pylori).

The company says around half of the global population is infected with H. pylori, which is found in 95 per cent of gastric cancer biopsies.

However, it says early-stage symptoms, such as indigestion, often remain overlooked, with current treatment options “limited and problematic”.

It is now using seed funding to support clinical trials to validate its treatment’s efficacy.

Furthermore, Lant Medical is working alongside the NHS to improve access to H. pylori testing, which it says will allow patients to obtain a test without the need for repeated GP visits.

Joanne Lant, Lant Medical chief executive, said: “We are incredibly grateful to Innovate UK for providing grant funding, to our angel investors for their belief and investment, and to UMI for making this possible.

“This funding marks a crucial step in our mission to develop a safer, more effective approach to treating H. pylori and improving global health.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.